Grabar Law Office is investigating claims on behalf of shareholders of Phreesia, Inc. (NYSE: PHR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Phreesia provides an integrated healthcare technology platform that combines software, payment, and patient engagement solutions designed to help healthcare organizations improve access to care, affordability, administrative efficiency, and patient outcomes. The company’s platform is embedded into healthcare provider workflows and patient interactions, supporting the patient journey from appointment scheduling and intake through payment and post-visit engagement. Phreesia serves ambulatory practices, hospitals, health systems, life sciences companies, government entities, patient advocacy organizations, and other healthcare-related organizations. According to the company, its platform facilitated approximately 180 million patient visits during fiscal year 2026, representing roughly one in six ambulatory patient visits in the United States.

Phreesia generates revenue through three primary business segments: (1) Subscription and related services, which provide recurring software and workflow solutions to healthcare providers; (2) Payment solutions, which include payment processing and financing-related services designed to help providers accelerate collections and cash flow; and (3) Network Solutions, which enables life sciences companies and other organizations to deliver personalized and compliant patient and provider engagement through Phreesia’s platform.

WHY? According to a recently filed securities fraud class action Complaint, it is alleged that Phreesia, Inc. (NYSE: PHR), through certain of its officers, made materially false and misleading statements and/or failed to disclose that: (1) Phreesia was experiencing slowing demand and diminished visibility into key revenue streams; (2) the Company's Network Solutions segment was facing weakened pharmaceutical marketing commitments; and (3) as a result, Defendants' positive statements about Phreesia's business, operations, and prospects lacked a reasonable basis and were materially false and misleading at all relevant times when made.

WHAT CAN YOU DO NOW? If you purchased Phreesia, Inc. (NYSE: PHR) shares prior to May 8, 2025, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.  Alternatively, if you purchased Phreesia shares between May 8, 2025, to March 30, 2026, you can participate in the class action.

#PHR #Phreesia $PHR